MabVax Therapeutics Holdings Inc
MabVax Therapeutics — Investor Presentation (September 2016)
31 slides from MabVax Therapeutics's investor presentation, Sep 6, 2016

Slide 1: Immuno-Oncology Products Discovered From The Human Immune Response to Cancer
NASDAQ: MBVX M MabVax W therapeutics Immuno-Oncology Products Discovered From The Human Immune Response to Cancer David Hansen President and CEO August 2016 Corporate Presentation QS =a

Slide 2: Disclaimer
DISCLAIMER Forward Looking Statements ‘This contains forward-looking statements and proj ‘The company makes no express or implied representation or warranty as to the completeness of this information or, in the case of the projections, as to their attainability or the accuracy and completeness of th

Slide 3: Key Highlights
KEY HIGHLIGHTS ° HuMab Discovery Platform: antibody-based products derived from the human immune response to cancer — Developed platform for antibody discovery resulting in portfolio of fully human antibodies = Integrated approach to of cancer d ti along, with Initial target is for pancreatic and GI

Slide 4: Key Highlights - Corporate and Financial
KEY HIGHLIGHTS - CORPORATE AND FINANCIAL @ Uplist to Nasdaq effective August 17th — Reverse stock split of 1 for 7.4 results in share price of $4.81 satisfying exchange — No requirement to trade for X days post-split basis = Price — reverse — uplist simultancously (Re-IPO) Closed on $9.4M financing

Slide 5: MabVax Discovery Platform: Therapies Derived From the Natural Human Immune Response
MABVAX DISCOVERY PLATFORM: THERAPIES DERIVED FROM THE NATURAL HUMAN IMMUNE RESPONSE immune response + Survey response across multiple patients + Single B-cell interrogation yields novel antibodies + Native human antibodies generated against validated vaccine antigens * Patient samples received from

Slide 6: HuMab-5B1 Demonstrates Integrated Antibody Clinical Development Platform
HUMAB-5B1 DEMONSTRATES INTEGRATED ANTIBODY CLINICAL DEVELOPMENT PLATFORM. > Therapeutic Antibody (MVT-5873) + Demonstrate safety, tolerability as single agent + Phase I trial initiated February 2016 with early read on trial 3QU6 + Clinicat'Trials.gov Identifier: NCT02672917 * Clear all dosage levels

Slide 7: MabVax Has Rich Pipeline of Product Candidates
MABVAX HAS RICH PIPELINE OF PRODUCT CANDIDATES “ae ja Commercial Program Indication Collaborators Discovery Pre-IND Phase1_— Phase2_“°R MVr5873 See ee NIH MSKCC, en, a ‘Therapeutic me ‘CRI, Patheon MYT-2163 NIH, MSKCC, PET-Imaging SCRI, Patheon Bag Metastatic Pancreatic MVT-1075 bance x —==- Ease ne

Slide 8: Lead Antibody Program - HuMab-5B1
LEAD ANTIBODY PROGRAM — HUMAB-5B1 SLEA ANTIGEN EXPRE 3D ON MULTIPLE SOLID TUMOR CANC —— sexcimtce ¢ HuMab-5B1 derived from a patient vaccinated ba with MabVax vaccine licensed from MSKC! ‘eras ie + Patients repeatedly vaccinated to drive immune Osu tae response against cancer antigen BcaI9 * Patient

Slide 9: Sialyl Lewis A As a Target for Cancer Therapeutics
SIALYL LEwis“ As A TARGET FOR CANCER THERAPEUTICS ° Sialyl Lewis A antigen (CA19-9) is the most frequently utilized and only validated serum marker for .ent of pancreatic cancers ° Aberrant glycosylation results in of sLe* and facilitates tumor proliferation, invasion, and metastatic spread! ° High

Slide 10: HuMab-5B1 Has Ideal Characteristics That Enable Development of Product Platform
HUMaAB-5B1 Has IDEAL CHARACTERISTICS THAT ENABLE DEVELOPMENT OF PRODUCT PLATFORM Characteristic Technical Description Advantage of HuMab-5B1 “Targeting cancer cell Binds tightly to target cell Cytotoxicity Does not target normal cells Additive effect with chemo therapy Ability to attach additional a

Slide 11: HuMab-5B1 Antibody Target Significantly Overexpressed on Multiple Cancers
HUMaAB-5B1 ANTIBODY TARGET SIGNIFICANTLY OVEREXPRESSED ON MULTIPLE CANCERS Potential therapeutic utility extends beyond pancreatic cancer ODP E. BK o¢ . Pancreatic ductal adenocarcinoma Colon carcinoma Lung adenocarcinoma Urinary bladder, mucinous adenocarcinoma Colon metastatic to ovary Breast carc

Slide 12: HuMab-5B1 Demonstrates Substantial Potentiation of Anti-Tumor Effect of SOC Chemotherapy in Pancreatic Cancer
HuUMAB-5B1 DEMO! TUMOR EFFECI OF SOC CH S$ SUBSTANTIAL POTENTIATION OF ANTI- EMOTHERAPY IN PANCREATIC CANCER RATE! Relative Tumor Growth at Day 42 Gemcitabine/nab-Paclitaxel as Baseline BxPC3 Xenograft Model SOC = Gemeitain [80mg/kg] and nab-Paciaxe [20mg /kg) 8 wth Rela<ve to Control (%) 8 soc SOC

Slide 13: HuMab-5B1 Demonstrates Substantial Anti-Tumor Effect in Small Cell Lung Cancer Model
HUMaAB-5B1 DEMONSTRATES SUBSTANTIAL ANTI-TUMOR EFFECT IN SMALL CELL LUNG CANCER MODEL — — Potentiation of Tumor Growth Inhibition and Growth Delay Seen When 2500 2000 8 1000 Tumor Volume (mm?) 500 M Mepyex Combined With Chemotherapy —e=Hu IgG Somg/kg (control) P= MVT-5873 25 me/kg = MVT-5873 50 mg/k

Slide 14: MVT-2163 HuMab Immuno-PET Imaging Agent
MVT-2163 HUMAB IMMUNO-PET IMAGING AGENT ° ° Significant unmet medical need for improved diagnosis and monitoring of pancreatic cancer Preclinical data demonstrate potential for new HuMab-5B1based PET agent Radiolabel abundant, commercially available, relatively inexpensive, & readily amenable to con

Slide 15: MVT-2163 Improves Imaging Compared to Standard Agent in Use Today
MVT-2163 IMPROVES IMAGING COMPARED TO STANDARD AGENT IN USE TODAY Mi i with BxPC3-luc p: a 4s "sg Me sta of FDO Acauied ”Z eno SB1anibody (725B1) Pa a ca of eine of hase mucosa Journal of Nuclear Medicine Acco of the nar high ape shih APCS nc mor senor (Nov. 2013) abc tes Received $1.75 Million NIH

Slide 16: Dual Labeled HuMab-5B1 May Provide Insights During Surgical Resection
DUAL LABELED HUMAB-5B1 May PROVIDE INSIGHTS DURING SURGICAL RESECTION Dual labeled HuMab-5B1 Zr & NIRF) retains targeting ability Suite-2 tumors and metast: visualized by PET and UV light Intra-surgical guidance for tumor resection can become feasible JL. Houghton. Si specifically labeled CA19.9-tar

Slide 17: MVT-1075 HuMab-5B1 Radioimmunotherapy (RIT)
MVT-1075 HUMAB-5B1 RADIOIMMUNOTHERAPY (RIT) @ Combines established efficacy of radiation therapy with tumor specific targeting @ Product has potential to deliver more potent HuMab-5BI1 based product @ Luis a low-energy radiation emitter with a relatively short tissue penctration range imum, 1.6 mm)

Slide 18: MVT-1075 Radioimmunotherapy Demonstrates Substantial Tumor Growth Suppression and Regression
MVT-1075 HUMAB-5B1 RADIOIMMUNOTHERAPY DEMONSTRATES SUBSTANTIAL ‘TUMOR GROWTH SUPPRESSION AND TUMOR REGRESSION ‘ 277Lu-CHX-A"-DTPA-5B1 jodistribution of #7” Lu-CHX-A”-DTPA-5B1 N=8 for all groups - ci ‘3 o og Time (days) ef & SF oe wv & Preferential tumor targeting with minimal distribution to non-tum

Slide 19: MVT-1075 Radioimmunotherapy: Orthotopic PDAC Model Demonstrates Tumor Regression
MVT-1075 HUMAB-5B1 RADIOIMMUNOTHERAPY ORTHOTOPIC PDAC MODEL DEMONSTRATES TUMOR REGRESSION Mirewvex Tumor Volume (mm) Tumor Growth -* Control (saline) > 177Lu-5B1 (300 iCi) Time after RIT Administration (days) All work done in collaboration with and inthe lb of Jason S Lewis, PhD. Member, Memoria ‘Sl

Slide 20: HuMab-5B1 Based Antibody Drug Conjugate (ADC)
HUMaAB-5B1 BASED ANTIBODY DRUG CONJUGATE (ADC) Schematic representation of the processes associate with the mechanism of action and biological activity of Antibody drug conjugates ° ° ° ° HuMab-5B1 has ideal characteristics for ADC Antibody is readily internalized Large number of targets on each cel

Slide 21: HuMab-5B1 Antibody Drug Conjugate Demonstrates Significant Efficacy in Multiple Tumor Cell Lines
HuMas-5B1 ANTIBODY DRUG CONJUGATE DEMONSTRATES SIGNIFICANT EFFICACY IN MULTIPLE TUMOR CELL LINES Pang e373 Paez cagana ‘ + searsoonn + resso0u z 8) Internalization of HuMab-5B1 j Into BxPC3 Pancreatic Cancer Cells Cenenaton a2 colts nh tat . eamon + ressos5040) z z test 3 i ‘mab Concentration (ol) T

Slide 22: HuMab-5B1 ADC In Vivo Linker Optimization Study Demonstrates Efficacy
HUMaAB-5B1 ANTIBODY DRUG CONJUGATE IN VIVO LINKER OPTIMIZATION STUDY DEMONSTRATES EFFICACY Wiganifurmor¥Glime: Group 01: PBs (10mL/ke) * SBI-ADC shows dose dependent croup 02h m Group 02: huS81-ADC (ama) funn peosvily te and regression at croup ot hus A0C3 (ame) : so0.00 | higher dose scious 05: huS

Slide 23: Early Feedback on MVT-5873 Phase I Clinical Trial
EARLY FEEDBACK ON MVT-5873 PHASE I CLINICAL TRIAL AS ‘THERAPEUTIC AGENT. @ Objectives of Phase I trial — Determine safety and tolerability as first line theray single agent and in combination with chemotherapy as 2 dose for both single agent and combination therapy 873 T'1.1) and duration of respons

Slide 24: Early Feedback on MVT-2163 Phase I PET Imaging Clinical Trial
EARLY FEEDBACK ON MVT-2163 PHASE I PET IMAGING CLINICAL TRIAL @ Objectives of Phase I trial — Determine safety as a single agent and in combination with MV'T-5873 as blocking dose — Determine recommended dose of MVT-5873 required for optimal tumor visualization — Determine optimal time interval betw

Slide 25: Status on MVT-1075 Phase I Radioimmunotherapy Clinical Trial
STATUS ON MVT-1075 PHASE I RADIOIMMUNOTHERAPY. CLINICAL TRIAL @ Objectives of Phase I trial Determine MTD and safety profile as a single agent Determine dosimetry of MVI-1075 Evaluate tumor response rate and duration of response Define a recommended Phase IT dos a single agent Expand Phase I to incl

Slide 26: Key Milestones for HuMab-5B1 Development Program
KEY MILESTONES FOR HUMAB5B1 DEVELOPMENT PROGRAM FOR — AND 2017 lopment 016 101 ram MVT-5873 ‘Therapeutic MVT-2163 PET Imaging HuMab-5B1 DC Next HuMab pment Candidate M MabVax + Initiate dose + Barly readout on + ‘Complete enrollment escalation safety fety and PK + Karly read Phase I Teal + Initiate

Slide 27: Robust Intellectual Property
ROBUST INTELLECTUAL PROPERTY @ issued patents and 3 pending applications in the U.S. — Issued patents covering monovalent and polyvalent vaccines, methods of use methods of manufacture, — 2 pending applications covering monoclonal antibodies @ 14 international patents and 3 pending applications = Is

Slide 28: Strong Management Team and Board of Directors
STRONG MANAGEMENT TEAM AND BOARD OF DIRECTORS J. David Hansen Arate, Xeneex Bitcienes, J. David Hansen Founder, President & CEO Dur Schering Plough, Ke, Bus Jeffery Ravetch, Philip Livingston, M.D, Memosil Sloan Kettering M.D., Ph.D Founder & Chief Science Officer “ances Center Avani Fest Comentooe,

Slide 29: Financial Information and Market Statistics
Financial Information and Market Statistics Cap Table (In Mils.) Pro Forma After Financing ed Post-Reverse Split $ 11.4 Cash and cash equivalents (as of June 30, 2016) $ 1.0 Monthly burn rate $ 5.0 Debt - Oxford Finance LLC Before Second Tranche* 4,235,339 5,641,350 Common stock outstanding. : 324,7

Slide 30: Differentiated Cancer Immunotherapy Company with Multiple Near-Term Milestones
DIFFERENTIATED CANCER IMMUNOTHERAPY COMPANY WITH MULTIPLE NEAR-TERM MILESTONES oa Novel antibody discovery platform producing multiple novel products with significant commercial potential @ Integrated and complementary development strategy leverages antibodies as superior targeting agents @ Therapeu

Slide 31: MabVax Therapeutics Company Contacts
NY MabVax therapeutics Immuno-Oncology Products Discovered From The Human Immune Response to Cancer Company Contacts David Hansen Gregory Hanson President and CEO Chief Financial Officer dhansen@mabvax.com gregoryhanson@mabvax.com 858-259-9405 x 301 858-259-9405 x 303
Source: SEC EDGAR · 8-K filed Sep 6, 2016
More decks from MabVax Therapeutics Holdings Inc
Investor Presentation (October 2018)19 slides · Oct 22, 2018
Virtual Investor Conference (May 2018)25 slides · May 3, 2018
Investor Presentation (February 2018)24 slides · Feb 12, 2018
Investor Presentation (September 2017)33 slides · Sep 12, 2017
Investor Presentation (August 2017)33 slides · Aug 24, 2017
Investor Presentation (June 2017)23 slides · Jun 23, 2017